RAF inhibitors that evade paradoxical MAPK pathway activation
about
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentChemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E ConformationKinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation CycleMolecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.The landscape of BRAF transcript and protein variants in human cancer.A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancerComprehensive pharmacological profiling of neurofibromatosis cell lines.Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma.SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.Precision medicine driven by cancer systems biology.CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies.Emerging targeted therapies for melanoma.Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.MicroRNAs in melanoma development and resistance to target therapy.Drugging RAS: Know the enemy.RAS Proteins and Their Regulators in Human Disease.Advances of small molecule targeting of kinases.Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicityContext-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.New somatic BRAF splicing mutation in Langerhans cell histiocytosis.PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.Overcoming resistance to BRAF inhibitors.Current Landscape of Targeted Therapy in Lung Cancer.Understanding and targeting resistance mechanisms in NSCLC.PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.
P2860
Q26751520-73762515-EE69-41ED-BE22-75E4A214CB16Q27727954-9EA0B230-40A5-4343-A3E6-ADC831EF7180Q28554490-4208E517-8800-4B5A-A6CA-929A05A124E7Q30391310-D069D265-0856-40E1-A1A4-96347605CA9FQ30395364-96A3C2EC-EFBC-4C24-A028-EFC0465E1CAAQ33617734-62DBBDE7-F0E6-477D-B6A6-4DDB3798CED0Q33621342-39801479-D4A5-4F88-9590-F7C872F30ACBQ33622690-69CB47FE-30B8-4238-8EC5-0B3C4DC62EE6Q33802043-693B6D21-F92E-409B-A34F-4F2A60E278E2Q36098356-E17263DF-D718-4D59-B9E0-9B983232B693Q36241608-5CA198A0-2720-4369-92CA-D25C00C5CC9AQ37451255-7F83B62F-6CD6-49CE-AD92-790E2837CB83Q37632230-6D03FC5D-D3A4-41B3-9442-775F308A8F0BQ37678108-8DEADBBF-9C2D-481D-9A43-5C6DEA48163FQ37708790-78F39021-9F8A-418D-B90B-6C76F82C6FF9Q37742635-9E5219F1-066C-4B2A-B987-6C43044C941FQ38625816-71C9EA10-720A-4E96-89CA-803E516ADD6FQ38634557-210E578B-0D14-4961-BFB7-8E5CE7848A5BQ38661348-81254686-9A8E-413A-A16A-5F958D2ACED9Q38721143-B116BDB3-C991-42A6-961F-256B696A36D8Q38752000-34BA3174-CE58-468B-941F-5356AF042329Q38814045-49DC6A96-21E8-44E5-A446-6B6AD6C5547CQ38826425-12C8D606-ED8B-436E-88DC-F94E2972B799Q38874383-BECACA62-2B9B-41EB-A5B3-D029DD3F9294Q38909389-E6CB0536-F65C-4F4D-814A-0F119A4ED1ECQ39101272-64A0400B-329A-41AE-899E-78469EAA0FA8Q39182842-63C1053F-B3D4-4ABF-86C5-A9249C36C838Q39407402-3BBE1508-8EB7-42AD-B567-70C7B92073EEQ39450797-C4C0BE64-8500-482D-AEB3-7176C538BDD2Q39734806-0D1EEBF9-3A76-4460-AADB-349547DF68B0Q41417492-63AEB353-62F6-4B9C-9F60-B677EDDDCDB1Q41862341-4CE9D5DA-37CE-4FFE-B6DD-AA5F35944171Q42331849-145C34A6-701F-4732-98CF-4C3B14EF0144Q42333715-221C856F-81C7-42BA-AE54-A492F41543DDQ42774672-CBA1B971-91DB-45B6-A02D-A2B57A04BEB9Q43298157-10F74BFD-7DAE-4FE9-8004-4E5F91AC10B1Q46034707-E6772132-AE30-4103-80E0-3960665D25E8Q46915997-C4FFEFB2-338A-4218-AF2B-B6FA9FF0DA25Q47142625-5C293FDD-ED1F-411B-AF99-F652F3ED3DECQ47144509-458BB32B-B697-4CF6-973D-067BA05FB1A1
P2860
RAF inhibitors that evade paradoxical MAPK pathway activation
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
RAF inhibitors that evade paradoxical MAPK pathway activation
@ast
RAF inhibitors that evade paradoxical MAPK pathway activation
@en
RAF inhibitors that evade paradoxical MAPK pathway activation
@nl
type
label
RAF inhibitors that evade paradoxical MAPK pathway activation
@ast
RAF inhibitors that evade paradoxical MAPK pathway activation
@en
RAF inhibitors that evade paradoxical MAPK pathway activation
@nl
prefLabel
RAF inhibitors that evade paradoxical MAPK pathway activation
@ast
RAF inhibitors that evade paradoxical MAPK pathway activation
@en
RAF inhibitors that evade paradoxical MAPK pathway activation
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
RAF inhibitors that evade paradoxical MAPK pathway activation
@en
P2093
Adhirai Marimuthu
Ben Powell
Bernice Matusow
Brian L West
Daniel Fong
Elizabeth A Burton
Emily Light
Garson Tsang
Gary Visor
Guoxian Wu
P2860
P2888
P3181
P356
10.1038/NATURE14982
P407
P577
2015-10-22T00:00:00Z
P6179
1006519725